Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.53 USD | +0.28% | +10.66% | -9.47% |
May. 09 | HilleVax, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 05 | Hillevax Insider Sold Shares Worth $264,467, According to a Recent SEC Filing | MT |
Valuation
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Capitalization 1 | 596.3 | 746.6 | 689.8 | - | - |
Enterprise Value (EV) 1 | 596.3 | 468.3 | 537.8 | 689.8 | 689.8 |
P/E ratio | -2.84 x | -5.28 x | -4.68 x | -4.53 x | -4.04 x |
Yield | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | 221 x |
EV / Revenue | - | - | - | - | 221 x |
EV / EBITDA | -9.16 x | -3.52 x | -3.31 x | -4.08 x | -3.26 x |
EV / FCF | -9.03 x | -4.8 x | -3.33 x | -4.22 x | -3.62 x |
FCF Yield | -11.1% | -20.8% | -30% | -23.7% | -27.6% |
Price to Book | 1.7 x | 2.88 x | 2.74 x | 2.97 x | 8.08 x |
Nbr of stocks (in thousands) | 35,644 | 46,516 | 47,475 | - | - |
Reference price 2 | 16.73 | 16.05 | 14.53 | 14.53 | 14.53 |
Announcement Date | 3/17/23 | 3/20/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | 3.125 |
EBITDA 1 | - | -65.11 | -132.9 | -162.5 | -169.3 | -211.5 |
EBIT 1 | - | -65.11 | -133.3 | -167.1 | -199 | -245 |
Operating Margin | - | - | - | - | - | -7,839.89% |
Earnings before Tax (EBT) 1 | - | -159.8 | -123.6 | -161.1 | -201.1 | -249.2 |
Net income 1 | -102.4 | -159.8 | -123.6 | -160.5 | -183.8 | -226.7 |
Net margin | - | - | - | - | - | -7,253.88% |
EPS 2 | -30.64 | -5.890 | -3.040 | -3.106 | -3.210 | -3.596 |
Free Cash Flow 1 | - | -66 | -97.53 | -161.4 | -163.5 | -190.7 |
FCF margin | - | - | - | - | - | -6,101.76% |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 2/28/22 | 3/17/23 | 3/20/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | -11.31 | -12.81 | -17.89 | -23.1 | -28.96 | -30.08 | -33.57 | -39.41 | - | - | - | - | - | - |
EBIT 1 | -11.31 | -12.81 | -17.89 | -23.1 | -28.96 | -30.18 | -33.91 | -40.29 | -49.8 | -43.49 | -39.74 | -38.85 | - | - |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -67.89 | -53.93 | -16.8 | -21.19 | -26.89 | -27.9 | -31.82 | -36.96 | -46.83 | -39.41 | -37.45 | -37.4 | - | - |
Net income 1 | -67.89 | -53.93 | -16.8 | -21.19 | -26.89 | -27.9 | -31.82 | -36.96 | -46.83 | -40.36 | -37.64 | -38.12 | - | - |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -10.06 | -2.030 | -0.4500 | -0.5600 | -0.7100 | -0.7400 | -0.8100 | -0.7800 | -0.9700 | -0.7954 | -0.7071 | -0.7000 | - | - |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 6/8/22 | 8/10/22 | 11/10/22 | 3/17/23 | 5/12/23 | 8/14/23 | 11/9/23 | 3/20/24 | 5/9/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | - | - | 278 | 152 | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | - | -66 | -97.5 | -161 | -163 | -191 |
ROE (net income / shareholders' equity) | - | - | -46.4% | -56% | -56.5% | -97.8% |
ROA (Net income/ Total Assets) | - | -71.9% | -37.4% | -43% | -43.5% | -68.2% |
Assets 1 | - | 222.2 | 330.8 | 373.6 | 422.6 | 332.2 |
Book Value Per Share 2 | - | 9.840 | 5.570 | 5.300 | 4.900 | 1.800 |
Cash Flow per Share | - | - | - | - | - | - |
Capex 1 | - | - | 10.7 | 2 | 6.5 | 6.5 |
Capex / Sales | - | - | - | - | - | 208.1% |
Announcement Date | 2/28/22 | 3/17/23 | 3/20/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.47% | 690M | |
+44.48% | 55.07B | |
+44.02% | 40.22B | |
-0.86% | 41.79B | |
-7.59% | 28.17B | |
+12.30% | 26.28B | |
-21.83% | 18.93B | |
+7.15% | 13.03B | |
+29.40% | 12.26B | |
+25.15% | 12.21B |
- Stock Market
- Equities
- HLVX Stock
- Financials HilleVax, Inc.